Skip to main content
. 2023 Feb 16;12(8):9373–9383. doi: 10.1002/cam4.5695

FIGURE 3.

FIGURE 3

Comparison of neurofilament light chain in serum in patients without nAE and those with nAE grade 3. EOS, end‐of‐study; FU, follow‐up; nAE, neurological adverse events; ns, not significant. ** p < 0.01. At each time point/study visit, n = 5 patients from each group were studied. None of the patients with nAE showed neurological symptoms at baseline.